Any benefit to getting the Berkeley test for cholesterol particle size over other markers of cvd risk?
Focusing on non-HDL-c (and/or ApoB), triglycerides, Lp(a), resting blood pressure, and blood sugar will get you the vast majority of what is needed here.
Changes in particle size distribution are often secondary to insulin resistance, which is already captured in the above metrics, so I do not routinely measure it. If we really wanted to go beyond the above metrics, I could probably make a better case for measuring inflammatory markers like hsCRP over particle size, based on interventional trials like the CANTOS trial and several recent trials looking at low-dose colchicine for cardiovascular disease.